The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells
Abygail G. Chapdelaine, Geng Chia Ku, Gongqin Sun, Marina K. Ayrapetov · 2023
Read The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells by Abygail G. Chapdelaine, Geng Chia Ku, Gongqin Sun, Marina K. Ayrapetov (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10741866.txt.
Description
Abygail Chapdelaine, Geng Chia Ku, Gongqin Sun, and Marina Ayrapetov probe why a gene-targeted drug fails in some colon cancers. Their 2023 study centers on a mutant gene called BRAF V600E, which drives cell growth in many cancers. Drugs against it work well in melanoma but often fail elsewhere.
The team uses a chimera drug that drags the mutant protein to destruction. The drug broke down the mutant in every cell line tried and cut a key growth signal. Yet killing power split sharply by cell line. Two lines died, while others only slowed in part. Lines with extra driver mutations resisted the drug most. One line also lost a partner protein, a quirk not seen elsewhere.
Catalog record
| CREATOR | Abygail G. Chapdelaine, Geng Chia Ku, Gongqin Sun, Marina K. Ayrapetov |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |